Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Disorders of the Female Reproductive System01:24

Disorders of the Female Reproductive System

4.5K
The female reproductive system can be affected by several disorders, including Premenstrual Syndrome (PMS), Premenstrual Dysphoric Disorder (PMDD), endometriosis, and various forms of cancer. PMS and PMDD are cyclical conditions that cause physical and emotional distress, with symptoms that include edema, mood swings, and food cravings. PMDD is a more severe form of PMS characterized by increased symptom severity that peaks during the luteal phase and tends to improve or resolve shortly after...
4.5K
Oogenesis02:07

Oogenesis

58.4K
In human women, oogenesis produces one mature egg cell or ovum for every precursor cell that enters meiosis. This process differs in two unique ways from the equivalent procedure of spermatogenesis in males. First, meiotic divisions during oogenesis are asymmetric, meaning that a large oocyte (containing most of the cytoplasm) and minor polar body are produced as a result of meiosis I, and again following meiosis II. Since only oocytes will go on to form embryos if fertilized, this unequal...
58.4K
Ovaries01:26

Ovaries

3.5K
The ovaries are roughly the size of almonds and measure approximately 2 to 3 centimeters in length. These paired structures are situated within the pelvic region and are anchored by the mesovarium—a peritoneal extension that also connects them to the wider structure of the broad ligament. The support system extends to the suspensory ligament, housing blood and lymphatic vessels. In addition, the ovarian ligament tethers the ovaries to the uterus.
On the ovarian surface, a layer of...
3.5K
Ovarian Cycle01:27

Ovarian Cycle

5.4K
The menstrual cycle includes a critical component known as the ovarian cycle, which undergoes two main phases each month—the follicular phase and the luteal phase. The follicular phase is variable and averaging around 14 days. Ovulation, triggered by a surge in luteinizing hormone (LH), marks the transition between the two phases. The second phase, the luteal phase, is relatively consistent, lasting approximately 14 days, and is marked by the activity of the corpus luteum. While a cycle...
5.4K
Cancer02:18

Cancer

51.7K
Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
51.7K
What is Cancer?02:12

What is Cancer?

12.8K
Cells and tissues must meticulously coordinate their activities for the normal functioning of the human body. Therefore, they exhibit socially responsible behavior - resting, growing, dividing, differentiating, or dying - for the organism’s benefit. Cancer arises when cells divide uncontrollably and invade other tissues or organs.
Although people have known about cancer for centuries, it was only in 1761 that Giovanni Morgagni of Padua performed a detailed autopsy of...
12.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cediranib with weekly paclitaxel or olaparib versus weekly paclitaxel for advanced or recurrent endometrial cancer (COPELIA): a multicentre, open-label, randomised, phase 2 trial in the UK.

EClinicalMedicine·2026
Same author

A case report of acute carcinoid heart failure during lutetium-177 dotatate-triapine treatment for well-differentiated neuroendocrine tumors.

Frontiers in oncology·2026
Same author

Phase Ib trial of SL-172154, a bispecific CD47 inhibitor and CD40 agonist Fc-fusion protein, in combination with mirvetuximab soravtansine or pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer.

British journal of cancer·2026
Same author

Ovarian cancer.

Nature reviews. Disease primers·2026
Same author

Approaches to optimize the benefits of immunotherapy and immunotherapy combinations across endometrial cancer types.

Journal of the National Cancer Institute·2026
Same author

Adjuvant Chemoradiotherapy Versus Radiotherapy Alone in Women With High-Risk Endometrial Cancer (PORTEC-3): 10-Year Clinical Outcomes and Post Hoc Analysis by Molecular Classification From a Randomized Phase 3 Trial.

Obstetrical & gynecological survey·2025
Same journal

Rethinking anticoagulation intensity during extracorporeal membrane oxygenation.

Lancet (London, England)·2026
Same journal

Standard-dose unfractionated heparin versus low-dose unfractionated heparin and low-molecular-weight heparin in extracorporeal life support (RATE): an open-label, randomised, non-inferiority trial.

Lancet (London, England)·2026
Same journal

Inherited retinal degenerations: clinical phenotypes and emerging therapies.

Lancet (London, England)·2026
Same journal

Documenting hospice care.

Lancet (London, England)·2026
Same journal

After the wood chipper.

Lancet (London, England)·2026
Same journal

Assisted dying and the silencing of medicine's next generation.

Lancet (London, England)·2026
See all related articles

Related Experiment Video

Updated: Apr 30, 2026

Author Spotlight: Advanced Ex Vivo Model for Investigating Cancer-Adipose Microenvironment Interaction
05:42

Author Spotlight: Advanced Ex Vivo Model for Investigating Cancer-Adipose Microenvironment Interaction

Published on: January 26, 2024

2.9K

Ovarian cancer.

Gordon C Jayson1, Elise C Kohn2, Henry C Kitchener3

  • 1Institute of Cancer Studies, Christie Hospital and University of Manchester, Wilmslow Road, Withington, Manchester, UK.

Lancet (London, England)
|April 29, 2014
PubMed
Summary
This summary is machine-generated.

Epithelial ovarian cancer, a leading cause of gynecological cancer death, often presents in advanced stages. While standard treatments exist, recurrent disease and chemoresistance are significant challenges, necessitating research into targeted therapies and screening.

More Related Videos

Transplantation Into the Mouse Ovarian Fat Pad
09:25

Transplantation Into the Mouse Ovarian Fat Pad

Published on: September 7, 2016

11.5K
Quantitation of Intra-peritoneal Ovarian Cancer Metastasis
10:58

Quantitation of Intra-peritoneal Ovarian Cancer Metastasis

Published on: July 18, 2016

10.4K

Related Experiment Videos

Last Updated: Apr 30, 2026

Author Spotlight: Advanced Ex Vivo Model for Investigating Cancer-Adipose Microenvironment Interaction
05:42

Author Spotlight: Advanced Ex Vivo Model for Investigating Cancer-Adipose Microenvironment Interaction

Published on: January 26, 2024

2.9K
Transplantation Into the Mouse Ovarian Fat Pad
09:25

Transplantation Into the Mouse Ovarian Fat Pad

Published on: September 7, 2016

11.5K
Quantitation of Intra-peritoneal Ovarian Cancer Metastasis
10:58

Quantitation of Intra-peritoneal Ovarian Cancer Metastasis

Published on: July 18, 2016

10.4K

Area of Science:

  • Gynecologic Oncology
  • Cancer Biology

Background:

  • Epithelial ovarian cancer is the most common cause of death from gynecological cancers.
  • The disease typically affects postmenopausal women and is often diagnosed at advanced stages (FIGO stage III).
  • Standard treatment involves surgery and platinum-based chemotherapy, which is curative for early stages but faces challenges with recurrent disease.

Purpose of the Study:

  • To review the current understanding of epithelial ovarian cancer, including its presentation, standard treatments, and challenges.
  • To explore emerging targeted treatments and the unproven efficacy of screening for early detection.

Main Methods:

  • Literature review of epithelial ovarian cancer epidemiology, clinical presentation, and treatment outcomes.
  • Discussion of standard surgical and chemotherapeutic approaches.
  • Exploration of novel targeted therapies, including antiangiogenic drugs and poly (ADP-ribose) polymerase inhibitors.
  • Assessment of the current status and future prospects of ovarian cancer screening.

Main Results:

  • Advanced stage epithelial ovarian cancer frequently recurs, leading to chemoresistance and a high mortality rate, primarily due to bowel obstruction.
  • While platinum-based chemotherapy can control responsive disease for years, most advanced cases experience recurrence.
  • Targeted therapies and improved screening methods hold promise for enhancing patient survival and early detection.

Conclusions:

  • Epithelial ovarian cancer remains a significant health challenge, particularly in its advanced stages, due to recurrence and chemoresistance.
  • Further research into targeted treatments and the validation of screening protocols are crucial for improving outcomes.
  • Effective management strategies are needed to combat the high mortality associated with this disease.